Paying user area
Try for free
Bristol-Myers Squibb Co. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Selected Financial Data since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Bristol-Myers Squibb Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Free Cash Flow to The Firm (FCFF)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The financial information indicates a generally stable pattern in both net cash provided by operating activities and free cash flow to the firm (FCFF) over the five-year period. While fluctuations exist, neither metric demonstrates a consistently strong upward or downward trajectory.
- Net Cash from Operations
- Net cash provided by operating activities decreased from US$16,207 million in 2021 to US$13,066 million in 2022, representing a notable decline. A subsequent recovery was observed in 2023, with the figure rising to US$13,860 million. This upward momentum continued into 2024, reaching US$15,190 million, before experiencing a slight decrease to US$14,156 million in 2025. Overall, the metric exhibits volatility but concludes near the level observed in 2021.
- Free Cash Flow to the Firm (FCFF)
- FCFF mirrored the trend observed in net cash from operations. A decrease from US$16,533 million in 2021 to US$13,100 million in 2022 was followed by an increase to US$13,795 million in 2023. FCFF continued to rise in 2024, reaching US$15,364 million, and then decreased slightly to US$14,433 million in 2025. The FCFF values closely track the corresponding values for net cash from operations, suggesting a strong correlation between the two.
The close alignment between net cash from operations and FCFF suggests that capital expenditure and other non-cash investing/financing activities have a limited impact on the overall free cash flow generation. The fluctuations observed across the period warrant further investigation to determine the underlying drivers, but the overall stability of these figures indicates a consistent ability to generate cash from core business operations.
- Comparative Analysis
- The difference between net cash from operations and FCFF remains relatively small throughout the period, consistently below US$300 million annually. This indicates that the adjustments made to arrive at FCFF, likely related to capital expenditures, are not substantially altering the overall cash flow picture.
Interest Paid, Net of Tax
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
2 2025 Calculation
Interest payments, tax = Interest payments × EITR
= × =
The analysis reveals fluctuations in both the effective income tax rate and interest payments, net of tax, over the five-year period. A notable divergence exists between the trends of these two financial items.
- Effective Income Tax Rate (EITR)
- The effective income tax rate exhibited volatility throughout the period. It increased from 13.40% in 2021 to 17.70% in 2022, then decreased significantly to 4.70% in 2023. A subsequent rise to 21.00% occurred in 2024, followed by a further increase to 24.40% in 2025. This suggests potential changes in the company’s income mix, tax planning strategies, or applicable tax laws.
- Interest Payments, Net of Tax
- Interest payments, net of tax, generally trended upward. A decrease was observed from $1,299 million in 2021 to $1,152 million in 2022. However, the subsequent years showed increases: $1,144 million in 2023, $1,422 million in 2024, and $1,588 million in 2025. This indicates a growing net interest expense over the latter part of the period, potentially due to increased debt levels or changes in interest rates.
The inverse relationship between the EITR and net interest expense is not immediately apparent, but the increasing net interest expense alongside a rising EITR in 2024 and 2025 could indicate a greater proportion of earnings being allocated to interest payments and taxes. Further investigation into the company’s debt structure and tax liabilities would be necessary to fully understand these dynamics.
- Combined Trend
- While the EITR experienced significant swings, the net interest expense demonstrated a consistent upward trajectory after the initial decrease. This suggests that, despite fluctuations in tax rates, the cost of financing has generally increased for the company over the observed timeframe.
Enterprise Value to FCFF Ratio, Current
| Selected Financial Data (US$ in millions) | |
| Enterprise value (EV) | |
| Free cash flow to the firm (FCFF) | |
| Valuation Ratio | |
| EV/FCFF | |
| Benchmarks | |
| EV/FCFF, Competitors1 | |
| AbbVie Inc. | |
| Amgen Inc. | |
| Danaher Corp. | |
| Eli Lilly & Co. | |
| Gilead Sciences Inc. | |
| Johnson & Johnson | |
| Merck & Co. Inc. | |
| Pfizer Inc. | |
| Regeneron Pharmaceuticals Inc. | |
| Thermo Fisher Scientific Inc. | |
| Vertex Pharmaceuticals Inc. | |
| EV/FCFF, Sector | |
| Pharmaceuticals, Biotechnology & Life Sciences | |
| EV/FCFF, Industry | |
| Health Care | |
Based on: 10-K (reporting date: 2025-12-31).
1 Click competitor name to see calculations.
If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.
Enterprise Value to FCFF Ratio, Historical
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Enterprise value (EV)1 | ||||||
| Free cash flow to the firm (FCFF)2 | ||||||
| Valuation Ratio | ||||||
| EV/FCFF3 | ||||||
| Benchmarks | ||||||
| EV/FCFF, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| EV/FCFF, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| EV/FCFF, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
3 2025 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =
4 Click competitor name to see calculations.
The Enterprise Value to Free Cash Flow to the Firm (EV/FCFF) ratio exhibits fluctuations over the five-year period. Initially, the ratio increased before declining and stabilizing. Enterprise Value decreased significantly in 2023 before partially recovering in subsequent years, while Free Cash Flow to the Firm remained relatively stable.
- EV/FCFF Ratio Trend
- The EV/FCFF ratio increased from 10.52 in 2021 to 13.87 in 2022, indicating a potentially higher valuation relative to the cash flow generated. A substantial decrease followed in 2023, with the ratio falling to 9.14. This decline suggests a more favorable valuation based on free cash flow. The ratio experienced a modest increase to 9.94 in 2024 and further to 10.84 in 2025, indicating a return towards the levels observed in 2021.
- Enterprise Value
- Enterprise Value increased from US$173,993 million in 2021 to US$181,761 million in 2022. A significant reduction occurred in 2023, falling to US$126,048 million. Subsequent years saw partial recovery, reaching US$152,789 million in 2024 and US$156,517 million in 2025. This pattern suggests potential shifts in the company’s market capitalization, debt levels, and cash holdings.
- Free Cash Flow to the Firm
- Free Cash Flow to the Firm experienced a decrease from US$16,533 million in 2021 to US$13,100 million in 2022. It then showed a slight recovery to US$13,795 million in 2023, followed by further increases to US$15,364 million in 2024 and US$14,433 million in 2025. The fluctuations, while present, were less pronounced than those observed in Enterprise Value, indicating a relatively stable cash-generating capability.
The interplay between Enterprise Value and Free Cash Flow to the Firm resulted in the observed EV/FCFF ratio trend. The decrease in the ratio in 2023 coincided with a substantial decline in Enterprise Value, while Free Cash Flow to the Firm remained relatively stable. The subsequent increases in the ratio in 2024 and 2025 reflect the partial recovery of Enterprise Value alongside continued, though slightly decreasing, Free Cash Flow to the Firm.